Partha Basu։ HPV-Based Cervical Screening Recommendations From the European Commission Initiative on Cervical Cancer

Partha Basu։ HPV-Based Cervical Screening Recommendations From the European Commission Initiative on Cervical Cancer

Partha Basu, Head of the Early Detection, Prevention and Infections Branch at International Agency for Research on Cancer (IARC), shared on LinkedIn:

“A major milestone for cervical cancer elimination in Europe.

IARC – International Agency for Research on Cancer / World Health Organization, in close collaboration with the European Commission Joint Research Centre (JRC), has led the European Commission Initiative on Cervical Cancer (EC-CvC) to develop updated cervical cancer screening recommendations for both HPV-vaccinated and unvaccinated populations in Europe.

Importantly, these recommendations are accompanied by a robust evidence base that can serve as a valuable reference for countries, professional societies, and healthcare organizations around the world as they update their own screening guidelines.

The work does not stop here. In collaboration with United Nations Population Fund (UNFPA), additional recommendations on the triage of HPV-positive women, colposcopy, and management of cervical precancerous lesions will be released in the coming months.

Evidence-informed policies and international collaboration remain central to accelerating progress towards cervical cancer elimination.”

Cervical Cancer Elimination in Europe

Burden of Cervical Cancer in Europe (2024 Estimates)

  • 58 901 new cases
  • 24 612 deaths (Source: Global Cancer Observatory: Cancer Today, 2024)

Key recommendations for HPV-based cervical screening from the European Commission Initiative on Cervical Cancer(EC-CvC)

  • Using validated HPV detection tests for cervical screening from age 25 years to age 64 years Either health-care provider-collected samples (validated DNA or mRNA tests) or self-collected samples (validated DNA tests) may be used.
  • Not using cervical cytology-based screening
  • Using longer screening intervals after a negative HPV test 5-year interval below age 40 years and 7-year interval from age 40 years, if previous HPV tests are negative.
  • Mailing validated self-collection kits for HPV testing with invitation to screening.
  • Among HPV-vaccinated populations Using a risk-stratified approach to decide on age of initiation and screening interval.

You can also read: Binay Shah: Scoping Review Explores Whether Newer HPV Tests Can Close the Cervical Cancer Screening Gap.